Competitor Analysis: Interleukin-23 & IL-12/23 Antagonists
Competitor Analysis: Interleukin-23 & IL-12/23 Antagonists
The Competitive Intelligence report about Interleukin-23 (IL-23) and IL-12/23 antagonists provides a competitor analysis of approved or being developed novel antagonists of interleukin-23 and IL-12/23 (p40 subunit) for treatment of psoriasis and other inflammatory diseases as of September 2015. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report provides a compilation of active products and projects on the market or in research and development as specific IL-23 or IL-12/23 (p40) antagonists as well as dual target IL-23 antagonists for treatment of immunologic diseases. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The Competitive Intelligence report about Interleukin-23 (IL-23) and IL-12/23 antagonists provides a competitor analysis of approved or being developed novel antagonists of interleukin-23 and IL-12/23 (p40 subunit) for treatment of psoriasis and other inflammatory diseases as of September 2015. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report provides a compilation of active products and projects on the market or in research and development as specific IL-23 or IL-12/23 (p40) antagonists as well as dual target IL-23 antagonists for treatment of immunologic diseases. Competitor projects are listed in a tabular format providing information on:
- Drug Codes
- Target/Mechanism of Action
- Class of Compound
- Company
- Product Category
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
IL-12/23 (p40) Antagonists
Selective IL-23 Antagonists
Dual Target IL-23 Antagonists
Corporate IL-23 & IL-12/23 R&D Portfolios
Selective IL-23 Antagonists
Dual Target IL-23 Antagonists
Corporate IL-23 & IL-12/23 R&D Portfolios
